Chadwick C. Prodromos M.D. is a board-certified orthopaedic surgeon and stem cell specialist in Chicago. He obtained his Bachelor’s degree from Princeton University, M.D. from Johns Hopkins Medical School, served a surgical internship at the University of Chicago, a residency in orthopaedic surgery at Rush University, and a fellowship in orthopaedic surgery and sports medicine at Harvard Medical School - Massachusetts General Hospital. He is the editor of the comprehensive textbook for orthopaedic surgeons on the ACL. He was assistant professor of orthopaedic surgery at Rush University for 27 years before stepping back to focus on his 501c3 nonprofit, Research and Education Foundation for Regenerative Medicine (TheFoReM.org). Dr. Prodromos is the founder and medical director of The Prodromos Stem Cell Institute (http://www.thepsci.com). The PSCI performs completely safe world-leading mesenchymal stem cell (NOT embryonic/fetal) treatment in Antigua, Buenos Aires, Argentina, and soon-to-be Athens, Greece. They attract and treat patients from all over the globe, including many high-profile elite professional athletes with their services. They offer extremely specialized stem cell treatment for a wide variety of disorders that are difficult or impossible to treat by other means. They have had success treating autoimmune diseases such as MS and rheumatoid arthritis as well as spinal cord injury, retinal disease, scleroderma, and autism, among many others. Alongside treating disorders and diseases, they are very active in the anti-aging and longevity space and have recently launched ELYSION (www.elysion.health), a truly evidence-based longevity website. Prioritizing evidence and science, the PSCI is one of the only stem cell institutes in the entire world that conducts research, regularly publishing their clinical trials, theories, and protocols in numerous papers in medical journals. They became the first group ever to effectively demonstrate a technique for regrowing human articular cartilage with long-term clinical success, published and reported in a PubMed-indexed journal and presented at a leading international meeting.
Effector/progenitor stem cell treatment in Buenos Aires.
T-cell vaccine (TCV) for the treatment of autoimmune disorders in Buenos Aires and Antigua.
Vitrobiopharma mesenchymal stem cell infusion in Antigua.
